You are viewing just a glimpse of the 100+ pieces of sophisticated insight and analysis produced by our full-time team of senior financial journalists every day. For full access, check to see if your firm has a license to The Deal Pipeline or login using your existing credentials.
Know your ID?
Username:
 
Password:
Go

Subscriber Content Preview | Request a free trialSearch  
  Go

Restructuring

Print  |  Share  |  Discuss  |  Reprint

Roche "disappointed" by Illumina poison pill

by Andrew Bulkeley  |  Published January 27, 2012 at 8:56 AM
roche227x128.jpgRoche Holding AG on Friday, Jan. 27, professed itself "disappointed," but not surprised, after Illumina Inc. adopted a poison pill to thwart the Swiss pharmaceutical company's $5.7 billion unwanted approach.

Illlumina Thursday said it would give investors who hold its shares Feb.

6 the right to buy one additional share for each six they hold as a dividend. The rights may only be exercised if someone acquires a 15% Illumina holding, increasing the cost of any approach.

The Basel-based medicine maker - the world's biggest producer of cancer treatments - kicked off its third major hostile approach this week after Illumina's board refused to discuss a deal. The Swiss company wants to add Illumina's gene-sequencing equipment to its own analysis activities and offer treatments targeted to the specific DNA of tumors.

"Roche's all-cash offer represents a substantial premium and Roche is confident that Illumina shareholders will see the value of the offer,"

the company said.

Analysts and investors see both the approach and resistance as less of a true hostile move and more as public posturing - and history backs up their assessment. Roche has twice used unwanted approaches to force adversaries to the bargaining table and hammer out a deal.

In 2008 it won over shareholders of Tucson, Ariz., tissue analysis company Ventana Medical Systems Inc. by sweetening an unwanted $3 billion bid to $3.4 billion.

That same year it convinced minority shareholders of San Francisco's Genentech Inc. to hand over the 44% stake it didn't already own by improving its offer to $46.8 billion from an initial $43.7 billion.

Roche is also proposing a change to Illumina's bylaws to allow it to propose a majority of its own executives to the target's board at the next shareholders meeting. No date has been set for the meeting but it can be no later than June.

Illumina shares pared 4.5%, or $2.50, Thursday to $52.65, well above the $44.50 per-share Roche plans to offer. Roche shares slipped less than 1%, or Sfr0.8, to Sfr159.40, in morning Zurich trade, valuing its entire equity at about Sfr139.4 billion ($151.8 billion).
Share:
Tags: Genentech Inc. | M&A | poison pill | Roche
blog comments powered by Disqus

Free preview

This is only a preview of The Deal's sophisticated coverage. Explore the real-time intelligence as researched and reported on by our team of financial journalists with a license to The Deal Pipeline. Click here for more information.

Meet the journalists

Andrew Bulkeley

Correspondent, Berlin

Andrew Bulkeley has been the Berlin-based European correspondent for The Deal for nearly a decade. Andrew has covered some of Europe's biggest deals, including the marriage and divorce of Daimler and Chrysler, Vodafone's record acquisition of Mannesmann, and the turbulent non-sale of General Motor's Opel. Contact



Movers & Shakers

Launch Movers and shakers slideshow

Royal Bank of Scotland's Alfred Carpetto joined KeyBank as executive vice president and head of the enterprise commercial payments group. For other updates launch today's Movers & shakers slideshow.

Video

Marsal: 'We need to have a boss of all regulators'

Bryan Marsal, CEO of Lehman Brothers, shares his views about what can be learned from Lehman's failure. More video

Sectors